REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 219 filers reported holding REATA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.91 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $50 | -100.0% | 500 | -64.3% | 0.00% | -100.0% |
| Q3 2021 | $140,000 | -23.5% | 1,400 | +7.7% | 0.00% | 0.0% |
| Q2 2021 | $183,000 | -71.1% | 1,300 | -68.0% | 0.00% | -66.7% |
| Q2 2020 | $634,000 | +15.5% | 4,068 | +6.8% | 0.00% | 0.0% |
| Q1 2020 | $549,000 | -29.4% | 3,810 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $778,000 | +47.3% | 3,810 | -42.3% | 0.00% | +200.0% |
| Q3 2019 | $528,000 | +36.8% | 6,600 | +61.0% | 0.00% | -50.0% |
| Q2 2019 | $386,000 | +19.1% | 4,100 | +7.9% | 0.00% | +100.0% |
| Q1 2019 | $324,000 | -52.1% | 3,800 | -82.6% | 0.00% | -66.7% |
| Q3 2017 | $677,000 | -1.7% | 21,800 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $689,000 | +347.4% | 21,800 | +220.6% | 0.00% | +200.0% |
| Q1 2017 | $154,000 | +4.1% | 6,800 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $148,000 | -17.3% | 6,800 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $179,000 | +383.8% | 6,800 | +257.9% | 0.00% | – |
| Q2 2016 | $37,000 | – | 1,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $76,391,000 | 14.09% |
| Opaleye Management Inc. | 330,000 | $8,702,000 | 1.85% |
| Highlander Partners, L.P. | 27,600 | $728,000 | 0.89% |
| Ikarian Capital, LLC | 200,000 | $5,274,000 | 0.79% |
| Integral Health Asset Management, LLC | 103,000 | $2,716,000 | 0.75% |
| KRS Capital Management, LLC | 32,841 | $866,000 | 0.74% |
| Ghost Tree Capital, LLC | 55,000 | $1,450,000 | 0.52% |
| MADDEN SECURITIES Corp | 39,312 | $1,037,000 | 0.49% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $801,000 | 0.47% |
| Ikarian Capital, LLC | 100,000 | $2,637,000 | 0.39% |